EPIC-19 Study
Application of convalescent plasma in the treatment of COVID-19 patients with metabolomic and laboratory assessment of plasma therapy progress.
MULTICENTER, INTERVENTIONAL, OPEN- LABEL CLINICAL TRIAL
Dear Participants,
We invite you to participate in the interventional clinical trial EPIC-19, which aims to expand knowledge about the novel SARS-CoV-2 virus and develop clinical practices for the treatment of COVID-19 patients. The study aims to identify differences in serological response among COVID-19 convalescent patients with different clinical symptoms or without clinical symptoms, in order to determine the impact of different antibody levels on the effectiveness of convalescent plasma therapy in COVID-19, while also looking at the molecular perspective of study participants' plasma and identifying metabolomic markers in the blood of donors and recipients that may affect and/or condition the clinical response to the applied convalescent plasma therapy.
